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Congenital deficiency of antithrombin III (AT III) is the only inherited hypercoagulable 
disorder for which a concentrate ofpurified protein is available for replacement therapy 
during periods ofincreased thrombotic risk. This report describes how such concentrates 
have been used in a patient with congenital AT-III deficiency undergoing venous urgery. 
A 40-year-old woman with AT III deficiency was evaluated for bilateral grade 3 chronic 
venous insufficiency. Noninvasive venous assessment and ascending venography revealed 
incompetence of the lower leg perforators, a patent deep venous ystem, and competent 
greater and lesser saphenous veins. Staged subfascial ligations were performed. Pasteur- 
ized AT III was administered 1 hour before surgery and at 30 hours at a dose calculated 
to increase AT-III activity to at least 120%. Perioperative AT III activity levels were 
measured. Subcutaneous heparin and oral warfarin were initiated the evening of surgery. 
An infusion of AT III increased plasma AT III from the baseline activity of 51% t ° 180%; 
it was 87% 13 hours later. Two measurements of the inidal half-life of AT III were 7 and 
14 hours. No perioperative thrombotic complications occurred. The ulcers healed, and the 
patient remains ymptom free. Pasteurized AT III concentrates are now commercially 
available, easily administered, and provide a useful adjunct to the anticoagulation regimen 
of patients with AT III deficiency undergoing vascular surgery. (J VASC St:R~ 1995;22: 
804-7.) 
Congenital deficiency of antithrombin III (AT 
III), first described in 1965,1 has a prevalence ofone 
per 2000 to 50002 and is one of the uncommon 
hypercoagulable syndromes. However, AT III defi- 
ciency is the only inherited disorder for which 
replacement therapy, comprised of concentrates of 
purified human AT III, has been approved by the 
Food and Drug Administration. The concentrates are 
pasteurized for viral inactivation. 3,4 Perioperative 
replacement therapy with antithrombin III concen- 
trate is recommended, because 17% to 24% of 
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patients with AT III deficiency undergoing surgery 
without receiving concentrates have development of
deep venous thrombosis, even when other forms of 
prophylaxis are used. s,6 Despite the commercial 
availability of the concentrates in the United States 
since 1990, clinical expericnce with their periopera- 
tive use in conjunction with anticoagulation has been 
limited. 
Previous studies in volunteers with AT III defi- 
ciency who have received concentrates indicate that 
AT III has a biphasic half-life that is 8 to 20 hours 
initially and then becomes more prolonged to 43 to 
92 hours.  2'7"9 For use in surgery the initial half-fife is 
the most important determinant in guiding therapy. 
This report describes the AT III activities achieved 
with concentrates in a patient with congenital defi- 
ciency with grade 3 chronic venous insufficiency who 
underwent wo separate procedures to ligate the 
lower leg venous perforators. On the basis of data 
obtained with this successfially treated patient and a 
review of the literature, guidelines are suggested for 
the use of AT III concentrates in vascular surgery. 
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Table I. Summary of  diagnostic tests 
Test Right leg Left leg 
Ascending venography 
Continuous-wave Doppler ultra- 
sonography 
Duplex ultrasonography 
Venous outflow/venous capaci- 
tance plethysmography 
PPG (venous filling time) 
Incompetent perforators, patent deep system 
Competent SFJ 
Incompetent perforators, patent deep system 
Competent SFI 
Incompetent perforators Not performed 
Normal Normal 
8 seconds 10 seconds 
SFJ, Saphenofemoral function; PPG, photoplethysmography. 
CASE REPORT 
The patient, an active dnty army first sergeant who is 
now 41 years old, was symptom-free until age 21 when she 
had development of left leg pain and was treated with 
analgesics. At the age of 24 she had development ofsimilar 
symptoms in the right leg, was diagnosed with deep venous 
thrombosis, and was treated with heparin followed by 3 
months ofwarfarin. Between the ages of 27 and 34, she had 
three additional episodes of lower extremity deep venous 
thrombosis. Laboratory evaluation performed when the 
patient was 34 revealed normal levels of protein S and 
protein C antigens and no evidence of antiphospholipid 
antibodies. However, the AT III activity was 55% (normal 
88% to 140%), and the AT II I  antigen was 7.5 mg/dl 
(normal 9 to 15 mg/dl). Anftthrombin III levels were de- 
termined with a functional assay with chromogenic sub- 
strate. 1° The deficiency was confirmed in a second sample. 
Lifelong warfarin therapy was initiated. The patient's 
mother and a 34 year-old brother, both ofwhom have had 
venous thromboembolism, also had AT III deficiency. 
At age 35 the patient received AT III as a volunteer to 
determine the half-life of the concentrate prepared by the 
American Red Cross under an Investigational New Drug 
(IND) application. The AT III showed an initial half- 
disappearance time of approximately 11 hours (Fig. 1), a 
raine similar to that in other reports, r'8 
The patient was referred to the vascular surgery service 
at age 35 with bilateral grade II I  chronic venous insuffi- 
ciency manifested by nlceration and bilateral leg pain 
during ambulation that impaired her ability to perform her 
military duftes. Treatment with elastic compression was not 
successful, and at age 39 the patient was evaluated for 
surgical treatment. On physical examination she had a 
recently healed ulcer at the leit medial malleolns with 
hyperpigmentation a d lipodermatosclcrosis. There were 
no varicose veins on either leg. Results of noninvasive 
venous testing and ascending venogräphy (Table I) were 
consistent with incompetence of the lower leg venous 
perforators. The patient was then scheduled for subfascial 
perforator ligation of the more symptomatic left leg. 
SLxteen months later a similar procedure was performed on 
the right leg because of symptom progression. 
Management of  perioperative anticoagulation. The 
plan for perioperaftve anticoagulafton included iscontinn- 
ation of warfarin 3 days before surgery and then reinstim- 
tion of warfarin (10 mg) daily beginning the evening of 
surgery along with subcutaneous heparin (10,000 nnits 
t-wo times daily). Pasteurized AT III (human) obtained 
from the American Red Cross as an IND was admin- 
istered 1 hour before surgery at a dose calculated to 
increase AT III activity to at least 120%. The goal of 
perioperative replacement was to maintain levels of 
AT III above 80% at all times during therapy, because 
values above this level are considered to be protective) 
The dose was calculated according to the following 
formula: Units required = (Desired percent plasma AT 
III activity - Baseline percent AT III activity) x Weight 
(kg)/1.2%. 
For this patient the initial dose was thus 
(120% - 51%) × 73.7 kg/1.2% = 4240 units. (One 
unit is the amount in one milliliter of plasma.) The value of 
1.2% is the assumed percent increase in the plasma level 
that will occur for each unit infused per kilogram body 
weight. This expected increase in the plasma level is 
provided by each manufacturer. This ranges between 1% to 
2% and can vary from patient o patient) ,8,9 
On the morning of surgery 4240 units of pasteurized 
AT III concentrate were administered intravenously, re- 
sulting in an immediate increase in AT II1 activity from 
51% to 180% (greater than expected because of a recovery 
of 2% rather than the lower estimate of 1.2%). The initial 
half-life was 7 hours (Fig. 2). Thirty hours after the initial 
AT III dose, the patient's measured AT III level was 73%, 
and an additional dose of AT III dose (2650 units) was 
given. After the second dose the half-life was 14 hours, 
which may reflect he effects of the first dose, as weil as the 
perioperative period. The patient was discharged on 
postoperative day 4 when her warfarin was therapeutic. 
For the second procedure 16 months later, the patient's 
anticoagnlation was managed according to the same 
protocol as for the first operation. The same AT II1 
replacement regimen was repeated for the second surgery 
with a commercially available concentrate (ATnativ; Kabi 
Pharmacia, distribnted by Baxter Healthcare Corp, Hyland 
Division, Glendale, Calif.). On the basis of the measured 
levels during the patient's first operation, the AT Il i dose 
was reduced to 3500 unit before surgery. She was given 
2500 units 29 hours later when the measured AT III 
activity had decreased to 62%. The cost of the AT III for 
the first procedure would have been approximately $8600 
(il it could have been purchased commercially then, rather 
than being obtained under IND from the American Red 
Cross) and was approximately $7500 for the second 
procedure when purchased from KABI through Baxter 
Healthcare. 
Surgical management and clinical outcome. For the 
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Fig. 1. Plasma AT III activity after infusion of AT III concentrate into patient during period 
of anticoagulation with warfarin during phase I smdy. The initial half-life is 11 hours. 
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Fig. 2. Plasma AT III activity after perioperative infusions of AT III concentrate during first 
venous surgery procedure. Initial half-life is 7 then 14 hours for two infusions. 
first procedure, a subfascial venous perforator ligation was 
performed through an incision along the length of the 
posterior border of the left tibia as described by Dodd and 
Cockett. n The ulcer above the left medial malleolus was 
excised at the inferior border of the incision and allowed to 
heal by secondary intention. Five to seven subfascial venous 
perforators were encountered and ligated. Sixteen months 
later a similar procedure was performed on the right leg. 
The patient recovered weh from both procedures. 
There were no thrombotic or bleeding complications. The 
patient experienced immediate and dramatic relief of leg 
pain after both operations and is now able to complete her 
required 2.5 mile walk (Army Physical Reädiness Test) in 
30 minutes without pain and is fit for duty. Ulceration has 
not recurred. The patient continues to wear elastic com- 
pression stockings. 
D ISCUSSION 
Although AT I I I  concentrates have been licensed 
in Europe since the mid 1970s, the data demonstrat- 
ing efficacy are based on retrospecrive studies and 
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small  series. 2,5,9 Tengborn and Berqvist, s in a small 
retrospective study in patients with deficiency undcr- 
going surgery, showed that when concentrates were 
used as prophylaxis, venous thromboembolism did 
not occur in any of 10 procedures, whereas the 
incidence was 19% for the patients with deficiency 
who received either no prophylaxis or prophylaxis 
that did not indu& AT III replacement therapy. Orte 
of the patients treated with AT III underwent two 
surgical procedures (details not provided) for treat- 
ment of chronic venous insufficiency, making this the 
only other eported case of AT III replacement during 
vascular surgery. Unfortunately, few details concern- 
ing dosage are provided, and there is no analysis of 
the AT III levels and pharmacokinetics. Schwartz et 
al. 2 administered AT III concentrates in five patients 
with congenital AT III deficiency for perioperative 
prophylaxis, one ofwhom also received heparin. No 
thrombotic omplications were reported. 
Measurement of AT III activity is recommended 
for adequate dosing. However, ifassays for AT III are 
not available, we suggest that the initial dose can be 
calculated on the basis of a presumed baseline level of 
50% for AT III activity according m the formula 
listed in the package insert, and, because the initial 
50% disappearance time is closer to 8 to 20 hours,  7'8 
a second ose can be given 10 to 12 hours later that 
is 50% of the initial dose. The literature describes the 
half-life of the purified AT III as between 43 and 92 
hours, but this is the terminai half-life and not the 
initia150% disappearance t ime. 2,9 This regimen of AT 
III replaccment in conjunction with prophylactic 
anticoagulation would provide adequate protection 
during periods of increased thrombotic risk. 
To minimize the cost of replacement therapy, 
which is approximately $0.60 to $1.00 per unit, 
AT III is administered in the operating room just 
before surgery, becanse fiall correction of the defi- 
ciency occurs as soon as the concentrate is adminis- 
tered. Because prophylactic anticoagulation can be 
initiated immediately before surgery, and in many 
cases, therapeutic anticoagulation can be started the 
evening of surgery, AT III replacement can often be 
discontinued after the second dose. For surgical 
procedures that contraindicate early therapeutic an- 
ticoagulation, such as many arterial reconstructions, 
or where prolonged immobilization is anticipated, a 
longer duration of AT III replacement might be 
necessary. 
This study proposes atemplate of AT III admin- 
istration with prophylactic anticoagulation during 
venous surgery. In patients undergoing arterial 
rcconstruction where therapeutic heparin anticoagu- 
lation is necessary, the dosage of AT III might need 
to be higher, or a repeat dose given sooner, because 
heparin has been shown to cause plasma AT III levels 
to decrease) 2 Although our study did not specifically 
address this issue, redosing AT III can be guided by 
closer monitoring of AT III levels within the first 12 
hours during heparin treatment. 
AT III concentrates are commercially available 
and easily administered for replacement therapy eren 
when AT III assays are not available. The use of AT 
III concentrates reduces the risk of perioperative 
thrombosis in patients with AT III deficiency tmder- 
going vascular surgery. 
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